Diagnostic value of biochemical markers of bone metabolism  in treatment of generalized periodontitis in patients with age-related osteoporosis by Fastovets, O.O. et al.
 Regul. Mech. Biosyst., 9(3) 
 
Regulatory Mechanisms  
in Biosystems  
ISSN 2519-8521 (Print)  
ISSN 2520-2588 (Online) 
Regul. Mech. Biosyst., 9(3), 315–321 
doi: 10.15421/021846 
Diagnostic value of biochemical markers of bone metabolism  
in treatment of generalized periodontitis in patients with age-related osteoporosis  
O. O. Fastovets, I. V. Masheiko, H. B. Peleshenko  
Dnipro Medical Academy of the Ministry of Health of Ukraine, Dnipro, Ukraine  
Article info 
Received 24.05.2018 
Received in revised form 
20.06.2018 
Accepted 23.06.2018 
 
Dnipro Medical Academy  
of the Ministry of Health  
of Ukraine, Vernadsky st., 9, 
Dnipro, 49027, Ukraine.  
Tel.: +38-097-992-11-24 
E-mail: fastovets.e@ex.ua 
Fastovets, O. O., Masheiko, I. V., & Peleshenko, H. B. (2018). Diagnostic value of biochemical markers of bone 
metabolism in treatment of generalized periodontitis in patients with age-related osteoporosis. Regulatory 
Mechanisms in Biosystems, 9(3), 315–321. doi:10.15421/021846  
The topicality of the problem of periodontal diseases is due to their significant prevalence. The purpose of this work 
is to study the dynamics of markers of bone metabolism in the process of treatment of generalized periodontitis of the 
II–III levels of severity in patients with age-related osteoporosis and without osteoporotic changes in the skeleton. 
The examination and treatment of 104 patients, aged 63–78, equal ratio of men and women, was conducted. Among the 
selected patients, 49 persons had normal bone mineral density, while the remaining 55 had osteoporotic changes in the 
bone tissue of involutory genesis. All subjects were assessed for the following indicators ; mineral density of jaw bone 
tissue (BMD) according to the results of the computer tomography, the concentration of C-Propeptide of Type I 
Procollagen (CICP) in blood plasma, the activity of tartrate-resistant acid phosphatase (TRAP), bone alkaline 
phosphatase (BAP), osteocalcin, parathyroid hormone in blood serum, concentration of β-CrossLaps in urine, total 
calcium and inorganic phosphorus content in blood with calculation of the Ca/P index. It was established that in patients 
with periodontitis of the II–III degree there was a decrease in the BMD of the alveolar bone in comparison with the 
control values (P ˂ 0.05), whereas the presence of systemic osteopenia worsened the indices (P ˂ 0.001). The least 
osteoregenerative activity, which was characterized by the decrease in BAP, TRAP and CICP levels, was registered in 
patients with generalized periodontitis of the III degree on the background of age-related osteoporosis (P ˂ 0.05). In the 
patients with generalized periodontitis of the III degree of severity, at the beginning of treatment, a weak negative 
correlation was found between BMD and TRAP activity (r = –0.292, P < 0.05) and mean strength correlation – with  
β-CrossLaps in urine (r = –0.348, P < 0.01). The concentration of CICP positively correlated with the mineral density of 
bone tissue from the third month after the start of treatment (r = 0.312, P < 0.05). As a conclusion, the mineral density of 
alveolar bone in the process of treatment varies unevenly depending on the severity of generalized periodontitis and the 
character of osteoporotic changes in the skeleton. The biochemical markers of bone metabolism allow the balance of 
processes of bone resorption and formation to be determined in order to correct treatment of generalized periodontitis.  
Keywords: periodontal diseases; osteopenia; bone mineral density; biomarkers.  
Introduction  
 
The problem of inflammatory-dystrophic diseases of periodon-
tal tissues is highly relevant on account of the wide distribution of 
this disease among the population of Ukraine, complicated by 
delayed diagnostics; the rapidly progressing development of the 
pathological process; and also by the necessity of integrated and 
prolonged treatment. Moreover, generalized periodontal disease is a 
serious socio-economic problem caused by a significant loss of 
teeth and decrease in the quality of life (Lu et al., 2016; Frencken 
et al., 2017). Currently, the diseases are classified as multi-factor di-
seases which are the result of interaction of the organism with the 
environment (Tsepov et al., 2016). Milder forms of generalized 
periodontal disease usually are nosologies, whereas severe forms 
are related to different systemic diseases which are characterized by 
general disorders of homeostasis (Fastovets, 2000; Linden et al., 2013). 
Practically always, hormonal disorders such as diabetes mellitus 
(Wu et al., 2015; Winning &Linden, 2017), endemic goiter (Chornij 
& Shmanko, 2017), menopause (Kolte et al., 2017; Goyal et al., 2017), 
states of immune deficiency, especially HIV infection (Souza et al., 
2017), leukemia (Rinčić et al., 2016), and disorders of the develop-
ment of connective tissue, for example its dysplasia (Kirova et al., 
2009, are associated with generalized periodontal disease.  
Currently, the pathogenic relation between the inflammatory 
process in the periodontal tissues and destructive changes in the 
alveolar cyst is proved (Wang & McCauley, 2016; Kinane et al., 
2017). However, recent research is not unanimous regarding the pe-
culiarities of the development of periodontal disease during osteo-
porotic changes in the skeleton (Darcey et al., 2013; Chambrone, 
2016), and also regarding the leading mechanism of destruction of 
the osseous component of periodontal disease (Bernal et al., 2018). 
It has been mentioned that with aggressive forms of periodontal 
disease, the number of osseous tooth deposits is minimum, whereas 
the resorption of bone tissue is significant (Clark et al., 2017).  
The bone tissue is a connective tissue with a high level of minera-
lization of organic intercellular substance which contains around 70% of 
non-organic compounds, mostly calcium phosphate. Despite the high 
level of mineralization, constant renewal of the matrix and adaptive 
restructuration occurs in the bone tissues depending on the conditions of 
their functioning (Sims & Gooi, 2008). The bone tissue`s resistance to 
resorption depends on the level of its mineralization, which is determi-
ned by the main factors (Penoni et al., 2016). The main factors which 
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influence the metabolism of bone tissue are the levels of calcium, phos-
phorus and hormones, which regulate their metabolism, circulating in 
the extracellular fluid (Naot & Cornish, 2008). The most informative 
markers of bone metabolism, often used in clinical studies, are 
considered to be the tartrate-resistant acid phosphatase (TRAP) of blood 
serum and C-terminal Telopeptide of Type-1 Collagen (β-CrossLaps) 
of urine, which reflect the activity of resorptive processes. At the same 
time, osteocalcin (ОС), bone alkaline phosphatase (BAP), procollagen 
type 1 C-terminal propeptide (CICP) of blood serum are most represen-
tative of the activity of processes of bone formation (Lu et al., 2016; 
Garnero, 2017). On the whole, the determination of the dynamics of 
concentration of the markers of resorption and formation of bone tissue 
in biological fluids is required in order to assess the success of treatment 
in effecting remission of the destructive processes in the bone tissue.  
Apart from the abovementioned biochemical studies, numerous 
noninvasive apparatus methods of diagnostics have been developed 
and broadly introduced into clinical practice. They allow accurate 
determination of the mineral density of the bone tissue (Dobrovol'-
skaja et al., 2017). Thus, the usage of roentgenological investigation 
allows not only study of the structure of bone tissue of the perio-
dontal complex, but also determination of whether the patient is in 
the risk group of development of periodontal disease (Gajdarova 
et al., 2006; Ignasiak et al., 2016), whereas the data from orthopa-
tomography are a reason for roentgenological densitometery (Naka-
moto et al., 2008).  
Finally, considering that systemic osteoporosis is a significant 
mechanism which leads to the development and complication of ge-
neralized periodontal disease (Bodduru et al., 2016), it is necessary 
to prescribe specific pathogenic therapy depending on the character 
of the metabolic disorders in the bone tissue (Gorb-Gavril'chenko & 
Strel'chenja, 2013; Aspalli et al., 2014; Mordasov & Ivanjuta, 2016). 
As a result of the close relationship between the mineral metabo-
lism and the pattern of systemic osteoporosis, many clinicians re-
commend combined pharmacotherapy using anti-resorptive prepa-
rations, calcium and vitamins (Karakov, 2016). Selecting the opti-
mum medicamental protocol, monitoring of the efficiency of treat-
ment in dynamics, which includes timely correction, is impossible 
without determining and monitoring the structural-functional condi-
tion of the bone tissue (Masheiko, 2017; Roschger et al. 2008).  
Therefore, considering everything stated above, the objective of 
this study was to determine the dynamics of biochemical markers of 
metabolism of bone tissue in the process of treatment of generalized 
periodontal disease of II–III degree among patients with age-related 
osteoporosis and no osteoporotic changes in the skeleton.  
 
Materials and methods  
 
For realisation of the goal, we conducted an integrated study and 
treatment of 104 patients with generalized periodontal disease of II–
III degree, aged between 63–78 years, with an equal number of men 
and women. To diagnose periodontal disease, we used the classifica-
tion of M. F. Danilevskij (Danilevskij & Borisenko, 2000).  
Among the selected patients, 49 had normal mineral density in 
the bone tissue, whereas 55 had osteoporotic changes in bone tissue of 
involute genesis. The condition of bone tissue was determined on the 
bases of the results of studying the mineral density of the bone tissue 
(BMD) using the method of dual-energy X-ray absorptiometry using 
the Lunar Prodigy apparatus. Measurements were made in the lumbar 
vertebrae (LI-LIV), in the area of femoral neck (Neck), greater tro-
chanter (Troch), and Ward's triangle (Ward). Diagnosing osteoporotic 
changes in the skeleton was conducted in accordance with the recom-
mendations of the WHO, criteria T, i.e. in relation to the value of 
standard deviation (SD) from the normal parameters of peak bone 
mass of healthy individuals of a corresponding age. The SD value 
below 1 was considered normal, between 1 and 2.5 SD – osteopenia, 
below 2.5 SD – osteoporosis (Siris et al., 2014).  
Criteria for excluding patients from the scope of the study were as 
follows: the general diseases in the anamnesis, which could influence 
the mineral density of bone tissue; usage of medical preparations 
which contain mineral components; traumas and inflammatory disea-
ses of the bone-joint system, breach of the treatment protocol.  
Prior to the study, the patients gave written approval for being 
involved in the study.  
The patients were divided as follows: 55 patients with senile 
osteoporosis were included in the first main group, group I (12 men 
and 15 women, who had generalized periodontal disease of II degree 
of severity) and the second main group, group II, which included 10 men 
and 18 women with aggressive (III type) disease. The comparison 
group was formed similarly to the main group in relation to gender-
age and clinical criteria from people who had normal parameters of 
mineral bone density. Therefore, the comparison group I included 14 
men and 9 women with periodontal disease of the II type; the compa-
rison group II – 16 men and 10 women with periodontal disease of 
the III type. Also, as the control, we involved 20 people of the same 
age group with an equal number of men and women, with condition-
nally healthy periodontal tissues, who had no diagnosed osteoporotic 
changes in the bone tissue.  
All patients suffering from generalized periodontal disease recei-
ved complex treatment according to the generally accepted protocol 
(Borysenko et al., 2005). Prior to the treatment the patients underwent 
a professional hygiene regime of the oral cavity, which consisted of 
removing the sediments above and under the gums using the “Piezon-
Master” ultrasonic system and the “Vektor” system. For providing 
long term stabilization of the pathological process, the dental treat-
ment included therapeutic, surgical and orthopedic methods, and also 
consultations and treatment recommended by an endocrinologist.  
In the scope of the presented study, all the observed patients were 
monitored using computer tomographic scanning of the jaw bones 
(Morita, Japan, 2008) to determine destructive changes in the com-
pacted and trabecular bone, and at the same time determine the para-
meters of BMD in the following zones: alveolar, middle and apical 
horizontal, septal vertical. Alveolar horizontal was considered a con-
ventional line which lay along the crest of alveolar process; middle 
horizontal – line which lay  across the central part of interdental sep-
tum; apical horizontal – line which connects the tops of the roots, septal 
vertical – line which divides the alveolar line into equal parts in leng-
thwise direction. The density of the bone tissue was expressed in 
Hounsfield numbers (H).  
The conclusions on the activity of the processes of destructive 
bone tissue were made according to the level of the resorption mar-
kers. In the blood serum, we determined the activity of tartrate-resis-
tant acid phosphatase (TRAP) (u/l) using a set of Bone-TRAP (IDS). 
The concentration of β-CrossLaps fragments in the urine were deter-
mined using the Serum CrossLaps (Osteometer) test-system.  
For standard excretion of β-CrossLaps, we used the second spon-
taneous morning sample of urine with following normalization of its 
concentration to the amount of creatinine in the analyzed sample. 
The results were converted into ng β-CrossLaps to 1 g of creatinine.  
The activity of recovery of the bone tissue was determined accor-
ding to the concentration of procollagen type 1 C-terminal propeptide 
(CICP) in the blood serum, which was determined using the method of 
immune-enzymic analysis with Metra CIPC EIA Kit («Quidel Cor-
poration», USA) diagnostic set, bone alkaline phosphatase (BAP) in 
the blood serum using kinetic colorimetric method (U/l), osteocalcin 
with N-MID Osteocalcin ELISA (USA) test set.  
In addition, we calculated the parameters of mineral metabolism – 
concentration of parathyroid hormone in the blood serum using the 
“I-PTH ELISA” (DSL, USA) test-system; the content of total calci-
um in the blood by the colorimetric method with Ortho-CresolPhtha-
lein (Kapitanenko & Dochkin, 1988); the content of total non-organic 
phosphorus in the blood by the colorimetric method according to the 
reaction with Molybdenum-Vanadium reagent (mmol/l) (Kondrahin, 
2004) with following calculation of the Ca/P proportion.  
The obtained data were statistically analyzed in Statistica 6.0 
(Statsoft Inc., USA) pack using the calculation of the Student`s t-crite-
rion at normal distribution of the data and non-parametric Mann-
Whitney test criterion at not normal distribution. The normal distribu-
tion was calculated using the Shapiro-Wilk test criterion. Differences 
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at P < 0.05 were considered statistically reliable (Filimonova et al., 
2004; Filimonova & Fil’, 2005).  
 
Results  
 
As we see from the data provided in Table 1, in each group, the 
most significant changes in the bone tissue density which occurred as 
a result of the course of treatment were observed in the septal vertical, 
and also in the alveolar and middle horizontals, i.e. in the areas direct-
ly involved in the pathological process of generalized periodontal 
disease. At the same time, in the alveolar horizontal, the BMD para-
meters were higher (P ˂ 0.05), though the dynamics of the changes in 
the process of treatment were similar to other areas of the jaw bones 
(P ˃ 0.05). The lowest changes in BMD were observed in the apical 
horizontal, which is explained by the remoteness of this area from the 
inflammation source localized in the interalveolar septa (P ˂ 0.001).  
Separate mention should be made of the significant dependency 
of the peculiarities of localization of the destructive process on the 
BMD parameters among the patients with generalized periodontitis. 
In patients suffering from generalized periodontitis of the III type with 
predominant vertical type of destruction of the bone tissue, the BMD 
parameters in certain areas were reduced to 600 Н. The determined 
reduction of the mineral density was followed by disorders in the 
bone structure manifested by loss of clarity in the trabecular pattern, 
which was clearer in the upper part of the septa, enlargement of the 
intratrabecular cavities; thinning of the trabeculae. The described pat-
tern of the pathological process is related to its localization mostly in the 
areas of cancellous bone tissue, where the metabolic processes take 
place very actively. Thus, in the abovementioned observations, the 
bone tissue was affected by active resorption, which was manifested 
in rapid decrease in the BMD parameters.  
The greatest decrease in the BMD parameters was observed in 
the alveolar horizontal among the patients suffering from  generalized 
periodontitis which developed following systemic osteoporotic chan-
ges in the bone tissue (main groups I and II). The determined parame-
ters of these groups were higher compared to the comparison groups I 
and II by 12.3 ± 3.2% (P > 0.05) and 14.1 ± 3.5% (P > 0.05) on ave-
rage respectively and by 24.0 ± 4.1% (P ˂ 0.01) and 32.1 ± 4.6% (P ˂ 
0.001) respectively compared to the control group.  
However, later, in the process of treatment, we observed gradual 
normalization of the parameters of mineral bone density among the 
patients of both experimental groups (P ˂ 0.001). One month after the 
beginning of the treatment, the BMD parameters of the II group of 
comparison had practically normalized and were close to the parame-
ters of the control, maintaining at this level throughout the monitoring 
(P ˃ 0.05). In the II group of comparison, the BMD parameters reco-
vered gradually, which was manifested in clinical-X-ray stabilization 
of the pathological process in the periodontal tissues, though they did 
not equalize with the parameters of the control (P ˃ 0.05).  
At the same time, mineral density of the bone tissue of the pati-
ents with generalized periodontitis of the II type (main group I), des-
pite the treatment, remained practically unchanged, and 3 months after 
the beginning of the treatment it had increased only by 6.1 ± 1.8% 
from the initial parameters (P ˃ 0.05). A similar insignificant increase 
was recorded in the next monitoring period. By contrast, during the 
treatment, the patients of main group II were observed to have a nega-
tive dynamic of the BMD parameters. Therefore, 1 month after the 
beginning of the treatment, the mineral density of the bone tissue had 
decreased by 4.2 ± 1.2% on average from the initial parameters, and 
after 3 months – by 6.5 ± 1.8%, having stabilized and demonstrating 
an insignificant positive dynamic 6 months after the beginning of the 
treatment (P ˃ 0.05).  
The results of the conducted biochemical studies, presented in 
Table 2, indicated that the level of total calcium in the blood before the 
treatment of generalized periodontitis in the comparison groups was 
within the norm, whereas in the main groups, we recorded a statisti-
cally reliable decrease of this indicator compared to the control (P < 
0.05). A similar difference was observed during 3 months after the 
beginning of treatment in main group I. Moreover, in main group II, 
the normalization of the calcium level in the blood serum was not re-
corded even 6 months after the beginning of the treatment.  
Table 1  
The dynamic of parameters of the mineral density of bone tissue (BMD) in different areas of the alveolar process among the patients  
of the main groups (n = 49) and the groups of comparison (n = 55) during the treatment compared to the control (M ± m, n = 20)  
Group Alveolar horizontal Middle horizontal Apical horizontal Septal vertical 
Control 1244.2 ± 78.6   1397.7 ± 106.1 1324.1 ± 84.3 1276.3 ± 98.4 
Comparison 
І 
before treatment   1077.6 ± 127.2   1285.8 ± 107.3   1301.8 ± 142.4 1126.6 ± 152.7 
after 1 month   1024.6 ± 131.4 1257.8 ± 96.8   1328.7 ± 153.5 1103.8 ± 111.9 
after 3 months   1037.6 ± 118.4   1287.8 ± 129.9   1355.5 ± 162.1 1174.6 ± 98.8 
after 6 months 1193.3 ± 95.9   1341.4 ± 124.2   1343.8 ± 146.6 1216.7 ± 139.8 
ІІ 
before treatment    983.9 ± 10.3* 1131.4 ± 95.3   1298.1 ± 118.1 982.5 ± 102.4* 
after 1 month     978.4 ± 182.2 1145.2 ± 88.9   1316.4 ± 125.7 969.7 ± 96.8* 
after 3 months 1027.1 ± 18.3   1257.4 ± 120.1   1311.6 ± 131.5 1096.4 ± 128.3 
after 6 months   1144.6 ± 118.4   1314.2 ± 129.9   1320.8 ± 176.6 1177.6 ± 119.4 
Main 
І 
before treatment      945.4 ± 78.1**    1101.7 ± 100.6*   1139.4 ± 145.3 982.7 ± 106.5* 
after 1 month     958.2 ± 148.3 1145.8 ± 97.3    1032.6 ± 117.4* 1002.3 ± 93.4* 
after 3 months     967.7 ± 132.6   1159.6 ± 134.6   1150.1 ± 120.9 1020.8 ± 114.7 
after 6 months 1046.1 ± 84.5   1201.1 ± 107.8 1158.3 ± 14.7 1059.7 ± 138.2 
ІІ 
before treatment      844.8 ± 79.6***      978.3 ± 135.8*    1025.4 ± 115.1* 880.4 ± 125.3* 
after one month     812.7 ± 140.9*       936.1 ± 123.2**    1048.2 ± 105.4* 829.4 ± 136.1* 
after 3 months     795.6 ± 151.2*      922.8 ± 147.5*  1109.6 ± 123.6 826.3 ± 122.3** 
after 6 months     887.3 ± 133.8*   1020.5 ± 158.1  1143.5 ± 128.7 893.8 ± 133.4* 
Note: * – the difference is statistically reliable at P < 0.05, ** – P < 0.01, *** – P < 0.001 compared to the parameters of the control.  
In the experimental groups, at the beginning of the treatment, the 
level of phosphorus in the blood of patients with generalized perio-
dontitis of the III type was higher than the control parameters (P < 0.05), 
indicating the prevalence of the bone resorption over the processes of 
bone tissue formation, unrelated to the mineral density of the skeleton.  
However, in comparison group II, we recorded a decrease in the 
concentration of phosphorus in the blood serum to its normalization 
already in the 3rd month since the treatment began (P < 0.05). By contrast, 
in all patients of the main groups the level of blood phosphates re-
mainned significantly lower than the parameters of the control 
throughout the study. Also, the prevailing of bone tissue resorption over 
the processes of its regeneration was indicated by the Са/Р proportion 
which was much lower than 1.0. In the patients with generalised pe-
riodontitis in the main groups I and II this indicator equaled 0.82 ± 
0.08 and 0.63 ± 0.07 respectively (P < 0.05 compared to the control).  
As we see in Table 2, the systemic osteoporotic phenomenon among 
the patients with generalized periodontitis was manifested in increase 
in the concentration of β-CrossLaps fragments in the urine (P < 0.05). 
And despite the fact that during the study, the patients of the main 
groups I and II were observed to exhibit a tendency towards decrease 
in its secretion, this parameter remained heightened even during the 
period remote from the beginning of the treatment, which indicates 
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resorption which gradually involved previously unaffected areas of the 
alveolar bone, and also possible progression of osteoporotic changes 
in other areas of bone.  
A positive change in the process of bone recovery among the patients 
with generalized periodontitis was the normalization of the level of acid 
bone phosphatase  a month after the treatment started in the I main 
group and 3 months after the beginning – in main group II (P < 0.001). 
Similar dynamic indicates gradual transformation of progressive resorp-
tion of bone tissue in its latent process with following decrease in the 
total proinflammatory potential as a result of the treatment.  
Table 2  
Changes in the biochemical parameters of metabolism of bone tissue in the blood and urine of the patients of the main groups (n = 49)  
and comparison groups (n = 55) over the treatment process compared to the control (M ± m, n = 20)  
Group TRAP, U/l 
β-CrossLaps, 
ng/g 
creatinine 
Osteocalcin, 
ng/mol BAP, U/l CICP, ng/mol 
Parathormone, 
pg/mol 
Total blood 
calcium, 
mmol/l 
Total non-
organic 
phosphorus of 
blood, mmol/l 
Control 4.86 ± 0.14 1.02 ± 0.05 16.64 ± 0.43 10.73 ± 0.34 61.82 ± 2.45 47.84 ± 3.27 2.32 ± 0.11 1.91 ± 0.16 
Comparison 
І 
before treatment 5.20 ± 0.16 1.12 ± 0.09 16.45 ± 0.44 11.82 ± 0.43 60.73 ± 2.56 46.78 ± 3.41 2.21 ± 0.12 2.05 ± 0.21 
after 1 month 5.11 ± 0.17 1.09 ± 0.07 18.22 ± 0.48* 11.59 ± 0.33 68.02 ± 2.48 47.12 ± 3.37 2.18 ± 0.14 1.98 ± 0.18 
after 3 months 5.15 ± 0.08 1.04 ± 0.08 17.93 ± 0.57 11.52 ± 0.38 71.09 ± 2.63* 46.84 ± 2.82 2.38 ± 0.11 2.07 ± 0.15 
after 6 months 5.05 ± 0.13 1.06 ± 0.09 18.64 ± 0.65* 11.45 ± 0.34 64.30 ± 2.57 47.51 ± 3.25 2.29 ± 0.13 1.86 ± 0.12 
ІІ 
before treatment 5.68 ± 0.21* 1.22 ± 0.08* 15.31 ± 0.55 9.01 ± 0.58* 51.93 ± 2.89* 48.15 ± 2.92 2.12 ± 0.19 2.38 ± 0.14* 
after 1 month 5.34 ± 0.26 1.14 ± 0.11 16.97 ± 0.45 9.23 ± 0.67 75.42 ± 3.01** 48.02 ± 3.19 2.37 ± 0.14 2.31 ± 0.23 
after 3 months 5.24 ± 0.24 1.12 ± 0.09 19.14 ± 0.62** 9.55 ± 0.51 71.72 ± 2.92* 47.48 ± 3.91 2.41 ± 0.16 2.24 ± 0.19 
after 6 months 5.18 ± 0.17 1.09 ± 0.07 17.97 ± 0.56 9.76 ± 0.46 66.76 ± 2.61 47.12 ± 4.06 2.25 ± 0.14 2.03 ± 0.17 
Main 
І 
before treatment 5.59 ± 0.32* 1.26 ± 0.10* 14.61 ± 0.63* 8.69 ± 0.58** 47.85 ± 3.04** 59.22 ± 3.87* 1.85 ± 0.18* 2.04 ± 0.20 
after 1 month 5.02 ± 0.30 1.23 ± 0.12 16.31 ± 0.44 9.08 ± 0.56* 53.17 ± 2.58* 56.75 ± 3.09 1.95 ± 0.16 2.14 ± 0.16 
after 3 months 4.74 ± 0.27 1.27 ± 0.11* 15.57 ± 0.56 9.31 ± 0.53* 58.73 ± 2.85 53.16 ± 2.64 2.09 ± 0.15 1.92 ± 0.14 
after 6 months 4.81 ± 0.24 1.22 ± 0.08* 16.03 ± 0.48 9.42 ± 0.56 59.35 ± 2.63 53.73 ± 3.03 2.23 ± 0.17 1.85 ± 0.15 
ІІ 
before treatment 5.83 ± 0.28** 1.33 ± 0.10** 13.31 ± 0.59*** 8.39 ± 0.52*** 45.75 ± 2.93*** 61.49 ± 4.42* 1.74 ± 0.21* 2.35 ± 0.11* 
after 1 month 5.73 ± 0.25** 1.28 ± 0.11* 13.65 ± 0.62*** 8.58 ± 0.51** 48.23 ± 3.02** 58.61 ± 4.15* 1.79 ± 0.23* 2.30 ± 0.10* 
after 3 months 5.23 ± 0.33 1.30 ± 0.11* 14.15 ± 0.64** 8.80 ± 0.48** 54.37 ± 2.76* 48.03 ± 3.89 1.86 ± 0.21 2.18 ± 0.18 
after 6 months 5.16 ± 0.31 1.25 ± 0.10* 14.88 ± 0.59* 8.97 ± 0.45** 55.11 ± 2.54 47.22 ± 3.95 1.90 ± 0.19 2.16 ± 0.22 
Note: * – difference is statistically significant at P < 0.05, ** – P < 0.01, *** – P < 0.001 compared to the parameters of the control.  
The highest level of alkaline phosphatase, which indicates the 
active processes of collagen synthesis in the bone tissue, was observed 
among the patients of comparison group I, whereas, the patients of the 
main groups and comparison group II had low values of this parameter 
(P < 0.05). In the patients with generalized periodontitis of the III type, 
which followed osteoporotic changes in the skeleton, the activity of the 
bone alkaline phosphatase decreased from the control values by 21.8 ± 
4.2% (P < 0.001). The latter, perhaps, was caused by the inhibition of the 
functional activity of the osteoblasts which accompanied the damage to 
a large volume of the bone tissue, which occurred among the patients.  
At the same time, the level of parathormone in all the experimental 
groups remained within the norm, though in the main groups, we 
observed a tendency towards the increase of its level to the upper border 
of the norm, caused by low level of calcium in the blood. Excessive 
secretion of parathormone following the hypocalcaemia additionally 
activates osteoprotegerin, which justifies the prescription of the calcium 
preparations and vitamin complexes during treatment of destructive 
forms of generalized periodontal disease (Leonova et al., 2013; Hells-
tein et al., 2011).  
It is interesting that the dynamic of changes in the level procollagen 
type 1 C-terminal propeptide (CICP) in the blood plasma, which de-
scribes the activity of osteoblasts, was different from the pattern of 
changes of other parameters of osteoregeneration. The highest CICP 
level observed in comparison groups I and II indicates that despite that 
decrease in the mineral density of bone tissue of bones of the jaw and 
significant prevalence of bone resorption over osteosynthesis among the 
abovementioned patients, the process of bone tissue recovery is 
developing at a sufficient level. Also, we should mention that the CICP 
level in the blood plasma normalized 1–3 months after the beginning of 
the treatment among the patients of the comparison groups. However, in 
the patients of the main groups the initial CICP level, which was lower 
by 22.6 ± 4.0% compared to the control (by 26.0 ± 4.3% for the main 
group II), normalized only 3–6 months after the treatment (P ˂  0.05).  
The same dynamic was observed for the parameters of bone alka-
line phosphatase and osteocalcin (Table 2). However, due to significant 
variation of its parameters, the determined differences compared to the 
control were statistically unreliable (P  ˃0.05). On the whole, the deter-
mined difference of the parameters of the bone formation reflects the 
decrease in the activity of the osteoregeneration processes among the 
patients with generalized periodontitis, who had osteoporotic changes in 
the entire skeleton.  
After generalization and analysis of the quantitative parameters de-
termined for the experimental groups during different periods of the 
treatment, we conducted a correlation-regressional analysis for determi-
ning the most significant relations between the indicators of mineral 
density of the bone tissue (BMD) and biochemical markers of bone 
metabolism. For the abovementioned analysis, we selected the parame-
ters which changed the most during the treatment: mineral density of the 
bone tissue in the alveolar and middle horizontal, concentration of 
tartrate-resistant acid phosphatase (TRAP), bone alkaline phosphatase, 
procollagen type 1 C-terminal propeptide (CICP) in the blood and β-
CrossLaps fragments in urine. The calculated correlational relations are 
presented in the Table 3 and 4.  
Table 3  
Correlational relationships (r) between the parameters of bone tissue 
mineral density of the lower jaw in alveolar horizontal and 
biochemical parameters of bone tissue metabolism among the patients 
of the experimental groups during the treatment (n = 104)  
Group TRAP β-CrossLaps BAP CICP 
Comparison 
І 
before treatment   –0.325*   –0.315*   0.205 0.232 
after 1 month –0.282   –0.275*     0.252* 0.268 
after 3 months –0.216 –0.246 –0.178 0.271* 
after 6 months –0.188 –0.163   0.211 0.234 
ІІ 
before treatment   –0.368*    –0.386** –0.188 0.214 
after 1 month –0.327 –0.325   0.155 0.247 
after 3 months   –0.264*   –0.341*     0.236*   0.281* 
after 6 months –0.180 –0.307 –0.146 0.319** 
Main 
І 
before treatment   –0.325*   –0.345*   0.172 0.283 
after 1 month –0.276   –0.308* –0.134 0.250 
after 3 months –0.294 –0.286   0.180   0.341* 
after 6 months –0.209 –0.262     0.216*   0.294* 
ІІ 
before treatment   –0.292*    –0.348**   0.208 0.217 
after 1 month   –0.267*   –0.312*   0.141 0.194 
after 3 months –0.283   –0.285* –0.187   0.312* 
after 6 months –0.227 –0.251   0.235   0.282* 
Note: * – the difference is statistically reliable at P < 0.05, ** – P < 0,01.  
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After the relationships between the mineral density of the jaws in 
the alveolar horizontal (BMD) and parameters of bone tissue metabo-
lism were calculated, in the main groups and comparison groups, we 
found a relatively low and average negative relation between this 
parameter and TRAP concentration in the blood and β-CrossLaps in 
the urine during the first three months of monitoring (P ˂ 0.05). It is 
interesting that the further correlation of the abovementioned parame-
ters had a low level of probability (P ˃ 0.05), which indicates the 
impact of proinflammatory markers on the destruction of bone tissue, 
and, therefore, the values of the BMD parameters at the beginning of 
the treatment. However, during the treatment, the levels of the above-
mentioned markers gradually decreased and their impact on the 
parameters of bone mineral density was reduced (see Table 3).  
For both experimental groups, we calculated a low positive corre-
lational relationship between bone mineral density and CICP concen-
tration in the blood plasma, which had a sufficient level of significan-
ce, beginning from the third month of monitoring (P ˂ 0.05). In our 
opinion, it was present due to the BMD dependency on the balance 
between the proinflammatory and osteoregenerating factors, and its 
changes were caused by the increase in the activity of the processes of 
bone tissue mineralization which occurred in the final stage of osteo-
regeneration a few months after the beginning of treatment. At the 
same time, in comparison group I, the correlational relation was less 
significant due to lower loss of the bone mass, i.e. a lower impact of 
these markers on the bone mineral density parameter.  
During the comparison of bone mineral density of the alveolar 
process in the middle horizontal and the indicators of bone tissue 
metabolism (see Table 4) among the patients of the main group, we 
determined a statistically significant average negative relation in the 
main groups with β-CrossLaps concentration throughout the monito-
ring and a low relation with TRAP at the beginning of the treatment 
(P ˂ 0.05). In comparison group II, a similar pattern was determined 
until the third month of monitoring.  
Perhaps, the presence of the abovementioned relations is due to 
the fact that bone tissue of the alveolar process in the middle horizon-
tal is not directly involved in the inflammatory process in patients 
with generalized periodontitis, i.e., its resorption level is less than 
TRAP-conditioned, therefore following osteoporosis, the bone mine-
ral density depends also on other components of the bone homeosta-
sis. This is proved by the extent of correlation of this parameter, which 
remained quite high with the β-CrossLaps concentration (P ˂ 0.05).  
Table 4  
Correlation relations (r) between the parameters of bone mineral 
density of the lower jaw in the middle horizontal and biochemical 
parameters of bone tissue metabolism among the patients  
of experimental groups in the process of treatment (n = 104)  
Group TRAP β-CrossLaps BAP CICP 
Comparison 
І 
before treatment   –0.218*   –0.242*   0.145 0.232 
after 1 month –0.223 –0.197   0.242*   0.261* 
after 3 months –0.148   –0.236* –0.173   0.284* 
after 6 months –0.167 –0.192   0.215 0.220 
ІІ 
before treatment   –0.203*   –0.328*   0.262 0.237 
after 1 month   –0.176*   –0.222*   0.125   0.277* 
after 3 months –0.144   –0.291* –0.136   0.291* 
after 6 months –0.159 –0.247   0.182   0.269* 
Main 
І 
before treatment   –0.274*   –0.302*   0.153 0.186 
after 1 month –0.240   –0.268*   0.164 0.217 
after 3 months –0.193 –0.227   0.207   0.251* 
after 6 months –0.162 –0.245 –0.118   0.234* 
ІІ 
before treatment   –0.217*     –0.343**   0.151 0.226 
after 1 month   –0.182*   –0.322*   0.170   0.254* 
after 3 months –0.168   –0.279*   0.183*   0.272* 
after 6 months –0.151   –0.258* –0.174   0.308* 
Note: * – difference was statistically reliable at P < 0.05.  
Finally, a low positive correlational relationship between BMD 
and CICP concentration was determined in the comparison groups 
from the first month of monitoring, whereas in the main groups this 
began in the third month (P ˂ 0.05). This allows us to conclude that 
the CICP is good at reflecting the processes of osteoregeneration and 
remineralization of bone tissue which was not directly involved in the 
inflammatory-dystrophic process.  
Finally, we should summarize the data obtained over the treat-
ment of the patients with generalized periodontitis in the different 
experimental groups. The highest percentage of stable remissions 
6 months after the treatment begun was recorded in the Ist main group 
and the Ist comparison group, i.e. among the patients with generalized 
periodontitis of the II type, who had osteoporotic changes in the 
skeleton, or did not have them. The treatment efficiency parameters 
equaled 74.1 ± 8.4% (20 of 27) respectively for the Ist main group 
and 78.3 ± 8.6% (18 of 23) for the I comparison group (P ˃ 0.05). Far 
worse results were observed in the II comparison group (patients with 
generalized periodontitis of the III type with no systemic involutory 
osteoporotic changes of bones), where the clinical-X-ray stabilization 
of the disease was observed only in 53.8 ± 9.8% (14 of 26) of the 
observations (P ˂ 0.05). In the II main group, i.e. the patients with the 
periodontitis of the III type, which had developed following systemic 
osteoporotic disorders in the bone tissue, the stable remission 6 months 
from the beginning of the treatment was recorded only in 8 of 28 
patients (28.6 ± 8.5%, P ˂ 0.05). Therefore, the efficiency of the treat-
ment significantly decreases in patients with advanced development 
of the inflammatory-dystrophic process in the tissues around the teeth. 
At the same time, the presence of systemic disorders in the bone me-
tabolism complicates the clinical symptomatic, causes more signifi-
cant imbalance of the resorption-regeneration processes in the alveolar 
bone, and, therefore complicates the treatment.  
 
Discussion  
 
Generalized periodontitis should be analyzed as an inflammatory-
dystrophic multi-factor process in the tissues around the teeth, the 
development of which depends both on genetic predisposition and 
external factors, and also individual peculiarities of the metabolic 
profile of the patient, and finally, the systemic diseases suffered by 
this patient (Wu et al., 2015; Tsepov et al., 2016; Souza et al., 2017).  
Osteoporosis of involutary genesis is a non-favourable factor 
which complicates generalized periodontal disease, which, first of all, 
manifests in decrease of the bone mineral density (BMD), particularly 
the alveolar process (Bodduru et al., 2016). Considering the fact that the 
alveolar bone is within the source area of the inflammatory-destructi-
ve process initiated by the microbial invasion of the periodontal 
tissues, rapid progression of the bone resorption develops. Also, bone 
tissue with decreased mineral density has lower reserve potential for 
recovery, even after eradication of the main periodontopathogenic factors.  
Therefore, it is pretty clear that without determining the causes of 
systemic disorders in the bone tissue, and also their elimination, it is 
practically impossible to achieve prolonged remission of generalized 
periodontal disease and eliminate the risk of development of relapse 
and progression of the pathological process (Mordasov & Ivanjuta, 
2016). Thus, it is recommended to supplement the main complex treat-
ment of generalized periodontosis by calcium preparations, mineral 
complexes, and preparations which normalize metabolic processes, 
particularly in bone tissue (Hellstein et al., 2011; Leonova et al., 2013). 
Moreover, in cases of diagnosed osteoporosis of patients with genera-
lized periodontal disease, it is recommended to prescribe antiosteopo-
rotic preparations (Gorb-Gavril'chenko & Strel'chenja, 2013; Aspalli 
et al., 2014). In our opinion, such an approach is entirely justified. Ho-
wever, treatment of osteoporosis cannot be within the competency of 
only a periodontist and requires participation of specialists in the field.  
Certainly, prescribing antiresorptive preparations, as with monito-
ring the dynamic of changes in bone tissue as a result of treatment is 
impossible without determining the parameters of bone mineral den-
sity (BMD) and study of biochemical markers of bone metabolism.  
As the results of our study indicate, bone mineral density changes 
in a nonuniform manner depending on the severity of generalized pe-
riodontosis and manifestation of osteoporotic changes in bone densi-
ty. In our opinion, this is caused by the fact that the pattern of proces-
ses of destruction and recovery of the bone matrix is determined by 
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proinflammatory, osteomodeling and osteoregeneration factors, the 
proportion of which changes and determines the condition of bone 
tissue at different stages of treatment.  
The results we obtained indicate a close relationship between the 
treatment results and initial periodontal status of patients, i.e. much 
worse prognosis of treatment outcome in groups with higher level of 
disease severity, which is proved by the works by our colleagues 
(Bodduru et al., 2016; Bernal et al., 2018). On the other hand, we de-
monstrated that the systemic disorders in bone metabolism, particular-
ly involutory genesis, radically complicate the inflammatory-dystro-
phic process in the tissues around the teeth, decreasing the efficiency 
of treatment. Therefore, there is a need to adjust the treatment proto-
col for the abovementioned patients.  
 
Conclusions  
 
The most diagnostically valuable indicators of the condition of 
bone tissue of patients with generalized periodontal disease of II–III type 
of severity following involutory osteoporosis with no systemic chan-
ges in mineral bone density are the parameters of bone mineral densi-
ty of the alveolar bone (BMD), and also the β-CrossLaps level in 
urine and activity of tartrate-resistant acid phosphatase (TRAP) and 
bone alkaline phosphatase in the blood serum.  
The most representative indicator of the inflammatory-destructive 
process in periodontal disease is decrease in bone mineral density in 
the alveolar part of jaw bones. This parameter decreases in patients 
with II type of severity by 13.4 ± 3.2% compared to the control, and in 
patients with III type by 20.1 ± 3.5% (P ˂ 0.05). Systemic osteopenic 
phenomena cause even greater decrease in this parameter to values 
which in patients with generalized periodontosis of II type of severity 
were 24.0 ± 4.1% lower than the control level, and lower by 32.1 ± 
4.6% (P ˂ 0.001) in patients with ІІІ type.  
The lowest osteoregenerative activity occurred at the beginning 
of treatment of patients with generalized periodontal disease of III 
type, which followed systemic involutory osteoporosis. Therefore, the 
activity of bone alkaline phosphatase decreased by 21.8 ± 4.0% com-
pared to the control; tartrate-resistant acid phosphatase (TRAP) – by 
20.0 ± 3.9% respectively; concentration of procollagen type 1 C-ter-
minal propeptide (CICP) – by 26.0 ± 4.3% (P ˂ 0.05).  
The main proinflammatory markers on the BMD parameters gra-
dually decrease in the process of treatment, whereas the positive dy-
namic of osteogenerative parameters indicate processes of bone tissue 
recovery, which is recorded only from the third month of monitoring. 
The mineral metabolism parameters have only supportive significan-
ce for assessing bone metabolism.  
The patients suffering from generalized periodontal disease of 
III type of severity have a low negative relationship between mineral 
density of the alveolar part of the jaw bones and activity of TRAP in 
the blood (r = –0.292, P < 0.05) and relationship of average extent 
with concentration of β-CrossLaps in the urine (r = –0.348, P < 0.01). 
At the same time, concentration of procollagen type 1 C-terminal pro-
peptide positively correlates with bone mineral density from the third 
month after the start of the treatment (r = 0.312, P < 0.05).  
The diagnostic value of biochemical markers of bone tissue meta-
bolism consists in determining the balance in the processes of resorp-
tion and formation, at different stages of generalized periodontal di-
sease, which allows one to correctly select the treatment tactics, pre-
scribe the correct pharmacotherapy and prevent the development of 
complications.  
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